Category: 206362-80-3

Recommanded Product: 206362-80-3. So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic. Compound: 4-(Bromomethyl)-1-chloro-2-fluorobenzene, is researched, Molecular C7H5BrClF, CAS is 206362-80-3, about Discovery of potent, orally bioavailable ERK1/2 inhibitors with isoindolin-1-one structure by structure-based drug design.

Constitutive activation of MAPK (RAS/RAF/MEK/ERK) pathway is frequently observed in many tumors and thus has become an interesting therapeutic target for cancer therapy. Despite the successful development of BRAF and MEK inhibitors in clinic treatment, resistance often appears to re-enhance ERK1/2 signaling. Inspired by the central role of the ERK1/2 signaling cascade in cancer, we describe the scaffold-hopping generation of a series of isoindolin-1-one ERK1/2 inhibitors. Our new compounds could inhibit proliferation of KRAS and BRAF mutant cells lines at low nanomolar concentrations Compound 22a possesses acceptable pharmacokinetic profiles and showed considerable in vivo antitumor efficacy in a HCT-116 xenograft model, providing a promising basis for further optimization towards clin. ERK1/2 inhibitors.

This compound(4-(Bromomethyl)-1-chloro-2-fluorobenzene)Recommanded Product: 206362-80-3 was discussed at the molecular level, the effects of temperature and reaction time on the properties of the compound were discussed, and the optimum reaction conditions were selected.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Recommanded Product: 206362-80-3. So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic. Compound: 4-(Bromomethyl)-1-chloro-2-fluorobenzene, is researched, Molecular C7H5BrClF, CAS is 206362-80-3, about Discovery of potent, orally bioavailable ERK1/2 inhibitors with isoindolin-1-one structure by structure-based drug design.

Constitutive activation of MAPK (RAS/RAF/MEK/ERK) pathway is frequently observed in many tumors and thus has become an interesting therapeutic target for cancer therapy. Despite the successful development of BRAF and MEK inhibitors in clinic treatment, resistance often appears to re-enhance ERK1/2 signaling. Inspired by the central role of the ERK1/2 signaling cascade in cancer, we describe the scaffold-hopping generation of a series of isoindolin-1-one ERK1/2 inhibitors. Our new compounds could inhibit proliferation of KRAS and BRAF mutant cells lines at low nanomolar concentrations Compound 22a possesses acceptable pharmacokinetic profiles and showed considerable in vivo antitumor efficacy in a HCT-116 xenograft model, providing a promising basis for further optimization towards clin. ERK1/2 inhibitors.

This compound(4-(Bromomethyl)-1-chloro-2-fluorobenzene)Recommanded Product: 206362-80-3 was discussed at the molecular level, the effects of temperature and reaction time on the properties of the compound were discussed, and the optimum reaction conditions were selected.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Synthetic Route of C7H5BrClF. The protonation of heteroatoms in aromatic heterocycles can be divided into two categories: lone pairs of electrons are in the aromatic ring conjugated system; and lone pairs of electrons do not participate. Compound: 4-(Bromomethyl)-1-chloro-2-fluorobenzene, is researched, Molecular C7H5BrClF, CAS is 206362-80-3, about Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine. Author is Han, Minsoo; Song, Chiman; Jeong, Nakcheol; Hahn, Hoh-Gyu.

For a development of broad spectrum antidepressant 3-aminoazetidine derivatives, two series of compounds were explored by bioisosteric modification of 3-α-oxyazetidine. We synthesized 166 novel 3-aminoazetidine derivatives in series A and B, starting from Boc-protected 3-azetidinone (3) and Boc-protected 3-azetidinal (9) resp., through parallel syntheses. The inhibitory reuptake activities against serotonin (5-HT), norepinephrine (NE), and dopamine (DA) neurotransmitters were measured by the Neurotransmitter Transporter Uptake Assay Kit using the human embryonic kidney 293 (HEK293) cells stably transfected with the resp. three kinds of human transporters (hSERT, hNET, and hDAT). Our study aimed to identify compounds having relative inhibitory activities against hSERT > hNET > hDAT. Lead optimization including microsomal stability, CYP, hERG assay, Ames test, BBB, and PK study resulted in the identification of compound 10dL as a candidate for further studies.

Different reactions of this compound(4-(Bromomethyl)-1-chloro-2-fluorobenzene)Synthetic Route of C7H5BrClF require different conditions, so the reaction conditions are very important.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Dressman, Bruce A.; Tromiczak, Eric G.; Chappell, Mark D.; Tripp, Allie E.; Quimby, Steven J.; Vetman, Tatiana; Fivush, Adam M.; Matt, James; Jaramillo, Carlos; Li, Renhua; Khilevich, Albert; Blanco, Maria-Jesus; Smith, Stephon C.; Carpintero, Mercedes; de Diego, Jose Eugenio; Barberis, Mario; Garcia-Cerrada, Susana; Soriano, Jose F.; Schkeryantz, Jeffrey M.; Witkin, Jeffrey M.; Wafford, Keith A.; Seidel, Wesley; Britton, Thomas; Overshiner, Carl D.; Li, Xia; Wang, Xu-Shan; Heinz, Beverly A.; Catlow, John T.; Swanson, Steven; Bedwell, David; Ornstein, Paul L.; Mitch, Charles H. published an article about the compound: 4-(Bromomethyl)-1-chloro-2-fluorobenzene( cas:206362-80-3,SMILESS:ClC1=C(C=C(CBr)C=C1)F ).Synthetic Route of C7H5BrClF. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:206362-80-3) through the article.

Neg. modulators of metabotropic glutamate 2 & 3 receptors demonstrate antidepressant-like activity in animal models and hold promise as novel therapeutic agents for the treatment of major depressive disorder. Herein we describe our efforts to prepare and optimize a series of conformationally constrained 3,4-disubstituted bicyclo[3.1.0]hexane glutamic acid analogs as orthosteric (glutamate site) mGlu2/3 receptor antagonists. This work led to the discovery of a highly potent and efficacious tool compound I (hmGlu2 IC50 46 ± 14.2 nM, hmGlu3 IC50 = 46.1 ± 36.2 nM). Compound I showed activity in the mouse forced swim test with a minimal ED (MED) of 1 mg/kg i.p. While in rat EEG studies it exhibited wake promoting effects at 3 and 10 mg/kg i.p. without any significant effects on locomotor activity. Compound I thus represents a novel tool mol. for studying the impact of blocking mGlu2/3 receptors both in vitro and in vivo.

Compounds in my other articles are similar to this one(4-(Bromomethyl)-1-chloro-2-fluorobenzene)Synthetic Route of C7H5BrClF, you can compare them to see their pros and cons in some ways,such as convenient, effective and so on.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Ren, Li; Grina, Jonas; Moreno, David; Blake, James F.; Gaudino, John J.; Garrey, Rustam; Metcalf, Andrew T.; Burkard, Michael; Martinson, Matthew; Rasor, Kevin; Chen, Huifen; Dean, Brian; Gould, Stephen E.; Pacheco, Patricia; Shahidi-Latham, Sheerin; Yin, Jianping; West, Kristina; Wang, Weiru; Moffat, John G.; Schwarz, Jacob B. published an article about the compound: 4-(Bromomethyl)-1-chloro-2-fluorobenzene( cas:206362-80-3,SMILESS:ClC1=C(C=C(CBr)C=C1)F ).Recommanded Product: 206362-80-3. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:206362-80-3) through the article.

Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of I, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, I was selected for further preclin. evaluation.

Compounds in my other articles are similar to this one(4-(Bromomethyl)-1-chloro-2-fluorobenzene)Recommanded Product: 206362-80-3, you can compare them to see their pros and cons in some ways,such as convenient, effective and so on.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro, published in 2017-01-29, which mentions a compound: 206362-80-3, Name is 4-(Bromomethyl)-1-chloro-2-fluorobenzene, Molecular C7H5BrClF, Application of 206362-80-3.

Thiazolidinediones (TZD) function as potent anti-diabetic drugs through their direct action on the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ), but their therapeutic benefits are compromised by severe side effects. To address this concern, here we developed a potent “”hit”” compound, VSP-51, which is a novel selective PPARγ-modulating ligand with improved therapeutic profiles in vitro compared to the multi-billion dollar TZD drug rosiglitazone (Rosi). Unlike Rosi, VSP-51 is a partial agonist of PPARγ with improved insulin sensitivity due to its ability to bind PPARγ with high affinity without stimulating adipocyte differentiation and the expression of adipogenesis-related genes. We have determined the crystal structure of the PPARγ ligand-binding domain (LBD) in complex with VSP-51, which revealed a unique mode of binding for VSP-51 and provides the mol. basis for the discrimination between VSP-51 from TZDs and other ligands such as telmisartan, SR1663 and SR1664. Taken together, our findings demonstrate that: a. VSP-51 can serve as a promising candidate for anti-diabetic drug discovery; and b. provide a rational basis for the development of future pharmacol. agents targeting PPARγ with advantages over current TZD drugs.

In some applications, this compound(206362-80-3)Application of 206362-80-3 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Guo, Zhi-Hua; Yin, Yong; Wang, Cong; Wang, Peng-Fei; Zhang, Xing-Tao; Wang, Zhong-Chang; Zhu, Hai-Liang published the article 《Design, synthesis and molecular docking of salicylic acid derivatives containing metronidazole as a new class of antimicrobial agents》. Keywords: preparation salicylic acid metronidazole antibacterial; crystal structure; Antibacterial activity; Molecular docking; S. aureus TyrRS; Salicylic acid derivatives.They researched the compound: 4-(Bromomethyl)-1-chloro-2-fluorobenzene( cas:206362-80-3 ).Formula: C7H5BrClF. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:206362-80-3) here.

A series of novel salicylic acid derivatives containing metronidazole as Staphylococcus aureus Tyrosyl-tRNA synthetase (TyrRS) inhibitors have been synthesized and evaluated their biol. activities as potential antibacterial agents. Among these compounds, compound I exhibited the most potent antibacterial activity against Gram-pos. (S. aureus ATCC 6538 and Bacillus subtilis ATCC 6633) and Gram-neg. (Escherichia coli ATCC 35218 and Pseudomonas aeruginosa ATCC 13525) with MICs of 0.39-1.57 μg/mL and showed the most potent S. aureus Tyrosyl-tRNA synthetase inhibitory with 2.3 μM. Docking simulation was performed to insert compound I into the crystal structure of S. aureus Tyrosyl-tRNA synthetase active site to determine the probable binding model. These results suggested that compound I may be a promising antibacterial agent.

In addition to the literature in the link below, there is a lot of literature about this compound(4-(Bromomethyl)-1-chloro-2-fluorobenzene)Formula: C7H5BrClF, illustrating the importance and wide applicability of this compound(206362-80-3).

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Most of the natural products isolated at present are heterocyclic compounds, so heterocyclic compounds occupy an important position in the research of organic chemistry. A compound: 206362-80-3, is researched, SMILESS is ClC1=C(C=C(CBr)C=C1)F, Molecular C7H5BrClFJournal, Article, Research Support, Non-U.S. Gov’t, Organic & Biomolecular Chemistry called Rhodium(III)-catalyzed regioselective C2-amidation of indoles with N-(2,4,6-trichlorobenzoyloxy)amides and its synthetic application to the development of a novel potential PPARγ modulator, Author is Shi, Jingjing; Zhao, Guanguan; Wang, Xiaowei; Xu, H. Eric; Yi, Wei, the main research direction is rhodium catalyst regioselective amidation indole trichlorobenzoyloxyamide; PPARgamma agonist indole trichlorobenzoyloxyamide.Name: 4-(Bromomethyl)-1-chloro-2-fluorobenzene.

A new and efficient method for the direct regioselective C2-amidation of various functionalized indoles with several N-(2,4,6-trichlorobenzoyloxy)amides via Rh(III)-catalyzed C-H activation/N-O cleavage/C-N formation using the pyrimidyl group as a readily installable and removable directing group has been developed. With this method, a variety of valuable 2-amido indoles can be easily prepared under mild conditions with broad functional group tolerance and excellent region-/site-specificities. The results from biol. evaluation showed that compound I had a partial PPARγ agonistic activity and a strong PPARγ binding affinity with an IC50 value of 120.0 nM, along with a less pronounced adipocyte differentiation ability compared to the currently marketed anti-diabetic drug rosiglitazone, suggesting that further development of such a compound might be of great interest.

In addition to the literature in the link below, there is a lot of literature about this compound(4-(Bromomethyl)-1-chloro-2-fluorobenzene)Name: 4-(Bromomethyl)-1-chloro-2-fluorobenzene, illustrating the importance and wide applicability of this compound(206362-80-3).

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Research Support, Non-U.S. Gov’t, Journal of Organic Chemistry called Development of a Phase-Transfer-Catalyzed, [2,3]-Wittig Rearrangement, Author is Denmark, Scott E.; Cullen, Lindsey R., which mentions a compound: 206362-80-3, SMILESS is ClC1=C(C=C(CBr)C=C1)F, Molecular C7H5BrClF, Product Details of 206362-80-3.

An investigation into the use of phase-transfer catalysis for the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds is described. Initial studies focused on identifying viable substrate classes that would undergo selective [2,3]-rearrangement under phase-transfer catalysis. Under certain conditions, the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds takes place in the presence of a phase-transfer agent, providing a rare example of a phase-transfer-catalyzed unimol. reaction. In the course of this investigation, it was found that catalysis is dependent on several variables including base concentration, catalyst structure, and substrate lipophilicity. Preliminary testing of chiral, nonracemic phase-transfer catalysts has shown promising levels of enantioselectivity for future development.

There are many compounds similar to this compound(206362-80-3)Product Details of 206362-80-3. if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Related Products of 206362-80-3. Aromatic compounds can be divided into two categories: single heterocycles and fused heterocycles. Compound: 4-(Bromomethyl)-1-chloro-2-fluorobenzene, is researched, Molecular C7H5BrClF, CAS is 206362-80-3, about Cinnamonitrile Adjuvants Restore Susceptibility to β-Lactams against Methicillin-Resistant Staphylococcus aureus. Author is Speri, Enrico; Kim, Choon; De Benedetti, Stefania; Qian, Yuanyuan; Lastochkin, Elena; Fishovitz, Jennifer; Fisher, Jed F.; Mobashery, Shahriar.

β-Lactams are used routinely to treat Staphylococcus aureus infections. However, the emergence of methicillin-resistant S. aureus (MRSA) renders them clin. precarious. We describe a class of cinnamonitrile adjuvants that restore the activity of oxacillin (a penicillin member of the β-lactams) against MRSA. The lead adjuvants were tested against six important strains of MRSA, one vancomycin-intermediate S. aureus (VISA) strain, and one linezolid-resistant S. aureus strain. Five compounds out of 84 total compounds showed broad potentiation. At 8 μM (E)-3-(5-(3,4-dichlorobenzyl)-2-(trifluoromethoxy)phenyl)-2-(methylsulfonyl)acrylonitrile (26) potentiated oxacillin with a >4000-fold reduction of its MIC (from 256 to 0.06 mg·L-1). This class of adjuvants holds promise for reversal of the resistance phenotype of MRSA.

As far as I know, this compound(206362-80-3)Related Products of 206362-80-3 can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem